Binge eating disorder (BED) is the most common eating disorder and an important public health problem. It is characterized by recurrent episodes of excessive food consumption accompanied by a sense of loss of control over the binge eating behavior without the inappropriate compensatory weight loss behaviors of bulimia nervosa. BED affects both sexes and all age groups and is associated with med...

BACKGROUND Despite the overall high degree of response to pharmacotherapy, consensus is lacking on how to judge clinical response or define optimal treatment/remission when treating adults with attention-deficit/hyperactivity disorder (ADHD). This study examined clinical response and symptomatic remission in analyses of 2 studies of lisdexamfetamine dimesylate (LDX) in adults with ADHD. METHO...

Nancy Gómez E-LIS Editor for Argentina, LLAAR discussion list coordinator Teaching Assistant, Universidad Carlos III, Madrid, Spain and Paola C. Bongiovani Researcher and faculty member at Universidad Nacional de Rosario, Argentina Consultant at Ministerio de Ciencia, Tecnología e Innovación Productiva de Argentina –– technical point person for the ““Federated Network of Institutional Repositor...

PURPOSE To compare treatment adherence, discontinuation, add-on, and daily average consumption (DACON) among adults with attention-deficit/hyperactivity disorder receiving second-line lisdexamfetamine dimesylate (LDX) or atomoxetine (ATX), following methylphenidate. PATIENTS AND METHODS A retrospective cohort study using US commercial claims databases (Q2/2009-Q3/2013). RESULTS At month 12,...

OBJECTIVE To examine duration of efficacy in long-acting stimulant treatment of attention-deficit/hyperactivity disorder (ADHD) in clinical trials using analog classroom protocols. RESEARCH DESIGN AND METHODS Published reports of clinical trials examining duration of medication efficacy using analog classroom protocols were identified in a systematic literature search of PubMed, BIOSYS, and E...

Published online ahead of print: J Clin Psychiatry September 9, 2008: e1–e10 (pii: ej08m04166). Available at PSYCHIATRIST.COM © Copyright 2008 Physicians Postgraduate Press, Inc. e1 ttention-deficit/hyperactivity disorder (ADHD) is one of the most common psychiatric disorders, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Attenti...

INTRODUCTION The efficacy and safety of stimulants for the pharmacologic management of attention deficit hyperactivity disorder (ADHD) is well documented. The US Food and Drug Administration approval of additional classes of medication even within stimulant treatments expands the prescribing options for practitioners. The focus of this paper is the prodrug amphetamine stimulant, lisdexamfetamin...

OBJECTIVE To search for predictors of placebo response in clinical trials of lisdexamfetamine dimesylate for the treatment of DSM-IV-TR-defined attention-deficit/hyperactivity disorder (ADHD) in children and adults. METHOD We used data from 2 clinical trials: (1) a 4-week, phase 3, multicenter, randomized, double-blind, forced-dose, parallel-group study of children aged 6 to 12 years with ADH...

Lisdexamfetamine dimesylate (LDX) is a long-acting d-amphetamine prodrug used to treat attention-deficit/hyperactivity disorder (ADHD) in children, adolescents and adults. LDX is hydrolysed in the blood to yield d-amphetamine, and the pharmacokinetic profile of d-amphetamine following oral administration of LDX has a lower maximum plasma concentration (Cmax), extended time to Cmax (Tmax) and lo...